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Abstract
A hallmark of p53 function is to regulate a transcriptional program in response to extracellular and intracellular stress that
directs cell cycle arrest, apoptosis, and cellular senescence. Independent of the role of p53 in the nucleus, some of the anti-
proliferative functions of p53 reside within the mitochondria [1]. p53 can arrest cell growth in response to mitochondrial
p53 in an EJ bladder carcinoma cell environment that is naı ¨ve of p53 function until induced to express p53 [2]. TP53 can
independently partition with endogenous nuclear and mitochondrial proteins consistent with the ability of p53 to enact
senescence. In order to address the role of p53 in navigating cellular senescence through the mitochondria, we identified
SirT3 to rescue EJ/p53 cells from induced p53-mediated growth arrest. Human SirT3 function appears coupled with p53
early during the initiation of p53 expression in the mitochondria by biochemical and cellular localization analysis. Our
evidence suggests that SirT3 partially abrogates p53 activity to enact growth arrest and senescence. Additionally, we
identified the chaperone protein BAG-2 in averting SirT3 targeting of p53 -mediated senescence. These studies identify a
complex relationship between p53, SirT3, and chaperoning factor BAG-2 that may link the salvaging and quality assurance
of the p53 protein for control of cellular fate independent of transcriptional activity.
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Introduction
Mechanisms for nuclear p53 that mediate cellular senescence
are largely known, however, the biochemical role of p53 in other
organelle systems is less understood. Furthermore, the potential of
so –called ‘‘p53 bodies’’ that exist within distinct cellular
compartments to communicate between one another and with
the cellular infrastructure has not been carefully examined. Until
recently, the prevailing model for p53 function has been studied
primarily within the nucleus with the exception of studying the
stability of the p53 protein itself. A number of studies now confirm
that p53 can mediate a program of cellular fate independent of a
nuclear and transcriptionally- competent species of p53 through
the association of the permeable potential of the inner mitochon-
drial membrane that confers the release of pro -apoptotic caspases
[3]. Recent studies indicate that p53-induced senescence within
nuclear PML bodies is directly antagonized by the protein
deacetylase SirT1, a yeast Sir2 homologue found in mammals,
through the inactivation of p53 by deacetylation [4]. However, this
contention has been somewhat challenged on the basis that the
loss of SirT1 activity on p53 acetylation by a specific SirT1
inhibitor is likely compensated for by several others HDACs or
sirtuins independent of SirT1 and thus fails to clearly demonstrate
the unifying role for SirT1 on p53 -induced senescence [5].
Alternative rationale may place p53 elsewhere from SirT1 activity
in a cellular context to mediate cellular senescence.
Human sirtuins are NAD+-dependent protein deacetylases
expressed as a multigene family of seven distinct gene products
(SirT 1-7) widely expressed in different tissues and localized
within different subcellular compartments [6]. [7][8]SirT1
directly mediate transcriptional processes involving gene silencing
[9] and may regulate telomere function [10]. Additional findings
suggest that murine sirtuin 1 (SirT1) directly mediate deacetyla-
tion of p53 that disrupt normal developmental processes [11]. In
addition to SirT1, SirT3 is a member of the class I sirtuins, the
most conserved members of the Sir2 gene from S. Cerevisiae.
SirT3, which is primarily localized within mitochondria and
widely expressed in adult and fetal tissue, contains protein
deacetylase activity [12,13,14] and expresses the major propor-
tion of mitochondrial protein deacetylase activity [12]. A function
of SirT3, like SirT1 and 2, is to deacetylate histones specifically at
H4K16 where SirT3 translocation to mitochrondria was
identified only during cellular stress [15][16]. Furthermore,
SirT3 protects cardiomyocytes from stress –induced cell death
by deacetylating Ku70 and this promotes interaction of Ku70
with the proapoptotic protein Bax. Thus, under stress conditions,
increased expression of SirT3 protects cardiomyocytes, in part by
hindering the translocation of Bax to mitochondria [17] and is
linked to the blocking of the cardiac hypertrophic response [18].
Surprisingly, SirT3 –deficient mice fail to display any profound
phenotypic alterations in metabolism, cell growth, or adaptive
thermogenesis, even when metabolically challenged, suggesting
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sirtuins [19][20,21].
The need for the cellular translocation of p53 is in part guided
through the chaperoning and the tight quality control of p53 for
the proper conformation throughout cell compartments [22]. To
execute the proper folding and shuttling of p53 throughout
multiple cell compartments p53 relies on co-chaperoning factors
such as Hsp90 [23] and is independently associated with the
carboxyl terminus of Hsp70-interacting protein (or CHIP) to direct
proteosomal sorting of mutant p53 [24] and to salvage wild-type
or misfolded p53 from degradation [25]. However, the ubiquitin
ligase activity of CHIP on p53 is likely under tight regulation but
the mechanics behind this control remain unclear. It is suspected
that under various cellular and physiological conditions, and
within different cellular compartments, there are differential and
specialized roles of co-chaperones of p53 to accommodate the
need for highly -ordered p53 conformation. As a result p53 is likely
guided through several interactions with chaperones molecules
with some of those needed to salvage or restore normal properties
from mis-folded or mutant p53 species in different cell compart-
ments. As a component of the CHIP containing complex, the
BCL2 anthagene protein, BAG-2, was identified to inhibit CHIP
to control for the destructive activity of the CHIP ubiquitin ligase
on specific cellular proteins in vivo [26]. This may implicate BAG-2
as an important mediator that maintains the pools of native p53
throughout the cell. Recently, it has been reported that the tumor
suppressor protein Tid1 (mtHsp40) promotes p53 translocation to
mitochondria under hypoxic conditions to reinforce apoptosis, by
masking p53 from degradation ensuring the trafficking to
mitochondria [27].
In an effort to further elucidate alternative mechanisms
regulating p53-induced senescence, we previously found that
p53-induced senescence in EJ-p53 cells is characterized by a
dramatic decrease in mitochondrial membrane potential, which is
not responsive to agents that activate or inhibit the mitochondrial
permeability transition pore complex (PTPC), e.g. atractyloside
(ATR) and cyclosporin A (CSA), respectively, as well as decreased
expression of adenine nucleotide translocase (ANT), the major
protein in the mitochondrial inner membrane [28]. Furthermore,
increasing evidence suggests that mitochondrial isoforms of
normal p53 induce mitochondrial permeablization leading to the
release of apopotosis –activating caspases [29], whereas, some
tumor derived mutation fail to do this [30]. Interestingly, these
processes likely couple p53 to many mitochondrial functions that
include the redox pathways and energy metabolism of the cells
[14]. Despite the assumption that sirtuins benefit cell survival
through enzymatic processes, the precise substrates for this action
have yet to be determined. Although recent evidence suggest that
post-translational modification of p53 is not a requirement for
targeting p53 to the mitochrondria [31], not all post-translational
modifications have been excluded due to the lack of reagents
necessary to test for all post-translational modifications of p53. We
indicate that a synthetic p53 peptide can serve as a substrate for
SirT3 in vitro. In this study we identify the co -localization of p53
with both nuclear and mitochondrial markers. Additionally, we
identify the sirtuin protein SirT3, as a regulator of p53 –induced
senescence and a marker for cellular lifespan and survival. Finally,
we demonstrate that p53 interacts with the BAG-2 component of
the CHIP ubiquitin ligase complex through the domain specifying
mitochondrial –associated senescence domain (MASD) that
challenge the ability of SirT3 to avert senescence by p53. These
studies reveal a novel network whereby sirtuins and co-chaperones
of p53 may coordinate cellular senescence in response to the
presence of p53.
Results and Discussion
p53 fractionates and localizes with mitochondrial
proteins during p53 -induced senescence
EJ-p53 cells were harvested at different time points as indicated
(Fig. 1A)( +tet, -tet 2 hours, 4 hours, 6 hours,1 day, 2 days,3 days
and 4 days). Using a subcellular fractionation and sucrose step
gradient, total cell lysates, nuclear and mitochondrial fractions
were obtained. Specific nuclear and mitochondrial subcellular
organelle markers were used to trace p53 alongside the
fractionation procedure. Upon tetracycline withdrawal p53 was
detected in mitochondrial fractions as early as 4 h after and
persisted in all subsequent time points analyzed, e.g. -tet 6 h, 1 d,
2 d, 3 d, 4 d. From –tet 1 day to 4 days, p53 levels dimished
(Fig. 1A). However, p53 levels were higher in nuclear and total
cell lysates prepared from EJ-p53 cells over the same time course.
Immunohistochemical analysis using confocal imaging showed
p53 exclusively in mitochondria at –tet 2 h (Fig. 1B). At –tet 4 h,
p53 was detected at higher levels in the mitochondria with
concomitant appearance of p53 in the nucleus. p53 persisted in
mitochondria and the nucleus for the duration of the time course
studied (from 24 h through 24 d).
Structural requirements for p53 –induced senescence in
EJ-p53 bladder cacinoma cells
One of the profiles for p53 when overexpressed is growth
suppression and arrest [32]. Using the expression of the wild –type
form of p53, we have previously demonstrated the immediate
response that follows to p53 induction in the EJ bladder carcinoma
system is cellular growth arrest/premature arrest initiated by
transfected p53 [2,33]. We have mapped domains of p53 relevant
for premature growth arrest in EJ bladder carcinoma cells
expression by measuring levels of senescence –associated (SA) b
galatosidase activity [34] and levels of prohibitin as having an
counter-correlative relationship to growth arrest [35] by ELISA
and immunoblot analysis (Research Diagnostics, Inc.) from EJ-p53
cell lysates. To confirm the ability of p53 to induce cell growth
arrest we have transfected p53 plasmids into the EJ bladder
carcinoma cell line [36]. Using truncations of p53 within the
FLAG-tagged p53 cDNA plasmid constructs, designed to ablate
specific domains as shown (Fig. 2A), we assessed levels of SA b
galactosidase staining and prohibitin protein expression. Following
48 hours after transfection parallel experiments were performed
using cell lysates recovered for ELISA analysis and immunoblot-
ting for prohibitin (Fig. 2A & B). In performing these studies we
have identified the proline –rich (PRD) and DNA binding (DBD)
domains as important structural determinants for their relative
contribution in promoting SA-b galatosidase activity and decreases
in prohibitin levels. Results of these studies indicate a cumulative
contribution of the PRD and DBD in mitochondria -associated
senescence in the EJ bladder carcinoma cells (Fig. 2A & B).
However, significant contribution was made in p53 –induced
senescence when the DBD remained intact. Shown is the
summary of experiments conducted to determine the correlation
between different domains of p53 and the ability of the different
domains of p53 to stimulate senescence –associated (SA) b
galatosidase activity (Fig. 2A) are correlative with mitochondrial
occupation from electromicrographs of transfected cells (Fig. 2C).
Deletion of the PRD results in a substantial loss of growth arrest,
however, deletion of the DBD domains results in a greater loss in
cell growth arrest when compared to the full-length and wild type
form of p53 using tetracycline inducible expression. However,
absence of both PRD and DBD regions results in the complete loss
of SA-b galactosidase activity and a dramatic increase in
Regulation of p53 by Sirt3
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with SirT3 we used FLAG –p53 constructs shown (Fig. 2A) to
transiently transfect the EJ-p53 cell line, without the prior
induction of p53, and determine the association with endogenous
SirT3 from whole cell extracts. We identify that p53 requires the
central domain encompassing residues from 69 to residue 204 as
important for the interaction between p53 and SirT3 (Fig. 2D).
Rescue of the growth arrest phenotype by inducible p53
involves the mitochondrial NAD –dependent Sir2 –like
sirtuin protein, SirT3
Senescence can be a model system to identify genes that
mitigate p53 function involved in the development of cancer,
whereby, normal p53 function is compromised to promote
cellular transformation and extends cellular lifespan. In our effort
to demonstrate what specific factors can rescue the growth arrest
phenotype generated by inducible p53 expression in the EJ
bladder carcinoma cell system, we reasoned that the identification
of gene products bypassing growth arrest could allow us to
identify further regulatory mechanisms involved in averting the
early -immediate p53 -induced senescence programs, a likely
target for promoting oncogenesis [37]. With this aim, we
performed a functional screen for cDNAs that could avert the
growth arrest phenotype in the EJ –p53 inducible cell model. EJ –
p53 cells prior to senescence (24 pre-induction) were infected with
a retroviral MaRX cDNA library prepared from embryonic
mouse fibroblasts [38]. MaRX retroviral vectors have a loXp site
incorporated in the long-terminal repeat (LTR) and a mini-
plasmid between the LTRs for improved retroviral rescue. After
24 of mock infection, EJ –p53 cells were induced by withdrawal
of tetracycline resulting in complete senescence of control cells. A
senescence associated (SA) b-galactosidase staining was used to
monitor infected EJ-p53 following p53 induction for senescence
and growth arrest (Fig. 3D). Proliferating cells from the cDNA
library -infected plates were monitored for [
3H] thymidine
incorporation were pooled and integrated proviruses were
recovered by in vitro Cre recombinase excision, taking advantage
Figure 1. Analysis of p53 in subcellular fractions from senescent EJ-p53 cells. (A) Immunoblots using 50 mg protein of total cell lysate and
subcellular fractions (mitochondria and nuclear fraction obtained from a sucrose gradient) were subject to SDS-PAGE and subsequently transferred to
PVDF filters (Immobilon, Millipore Corp.). Blots were then blocked with BSA and initially probed using a mouse monoclonal antibody specific for p53
(clone 1801, Oncogene Research) followed by HRP-conjugated anti-mouse IgG (Roche) and then developed using ECL kit (GE Healthcare/Amersham).
Blots were reprobed using mouse monoclonal specific for the mitochondrial marker, Cox II (Molecular Probes, Invitrogen) and nuclear marker PCNA
(Calbiochem) followed by HRP-conjugated anti-mouse IgG and then developed using the ECL kit (GE Healthcare/Amersham). (B) Laser confocal
image of p53 immunohistochemistry and CMTMR, YOYO fluorescence in EJ-p53 cells. EJ-p53 cells were maintained in (+) tet (no p53 expression) and
(-)tet 2 hours through 4days (overexpression of wt p53). p53-specific mAb(Oncogene research) and Cy5-labled anti-mouse were used to
immunohistochemistry localize p53 in EJ-p53 cells. YOYO was used to stain nuclei and CMTMR was to stain mitochondria. For each image, p53 was
re-colored to red, Nuclei was re-colored to blue, and mitochondria was re-colored to green. p53 localization in p53-induced senescence in EJ-p53 cells
was determined by overlay.
doi:10.1371/journal.pone.0010486.g001
Regulation of p53 by Sirt3
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10486of the loxP site incorporated in the MaRX LTR.[38] Sequencing
of the recovered proviruses rendered several different cDNAs, but
only infection with retroviral clone A478-34, which contains a
2.9 kb insert representing the full cDNA coding for a NAD+
dependent Sir2 –like protein, SirT3, rescued EJ-p53 cells
completely from growth arrest.
There are seven mammalian Sir2 homologs (SirT1-7) [39], all of
which maintain the catalytic core domain homologous to yeast
Sir2. NAD-dependent protein deacetylase activity has been
demonstrated for mammalian SirT1, SirT2, and SirT3 proteins.
The presence of NAD-dependent ADP-ribosylase and protein
deacetylase activities of sirtuin proteins suggests that they may
Figure 2. Deletion of p53 identifies the novel mitochrondria -associated senescence domain (MASD) between amino acids 64 and
209 of p53. (A) Various deletions of FLAG –tagged p53 were used to determine involvement in mitochrondria –associated senescence programs in
EJ-p53 cells. The following abbreviations were used to characterize individual domains within p53 as, AD1, activation domain 1; AD2, activation
domain 2; PRD, proline rich domain; DBD-NLS-TD-NES, combined DNA binding domain-nuclear localization signal-transactivation domain-nuclear
export signal; BD, basic domain. Following the transient transfection of individual p53 constructs into the uninduced EJ-p53 cells, expression of p53
protein levels were normalized versus cell number to measure the level of SA -b galactosidase activity by staining with Xgal. ELISA analysis was then
performed using antisera against human prohibitin (Research Diagnostics, Inc.). Colormetric analysis was then used to measure the amount of SA-b
galactosidase activity ELISA was performed to measure prohibitin levels (fg/ml lysate) and normalized by the amount of immunoprecipitated FLAG-
tagged p53 protein used as input from the ELISA assay. (B) Immunoblot analysis was then performed with anti –prohibitin nitrocellulose filter was
reused to immunoblot with an anti- b actin polyclonal antisera (Sigma-Aldrich). (C) Electron micrograph (10,000X) of EJ carcinoma cells transfected
with the different FLAG-tagged and truncated variants of human p53 and stained with the anti-FLAG monoclonal antibody (Sigma-Aldrich). Region
corresponding to the outline of the mitochrondria is indicated. (D) Interaction of Sirt3 with the MASD region of p53. Using FLAG-tagged variants of
the deleted p53 cDNAs expressed by transient transfections of p53 shown (left) were used to identify specific interactions with endogenous Sirt3 by
immunoprecipitation with M2 agarose (Sigma-Aldrich) followed by standard immunoblotting protocols.
doi:10.1371/journal.pone.0010486.g002
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regulate cellular functions accordingly. Mammalian SirT1, which
resides in the nucleus, is the most closely related to yeast Sir2 and
SirT3 is most closely related to SirT1 [8]. SirT1 binds and
deacetylates p53 [40] NF-kB [41], and histones [42]. In contrast,
mSirT1-deficient cells are p53-hyperacetylated and have elevated
p53-dependent apoptosis, whereas, mSirT1 knock-out mice
exhibit developmental defects [11,14]. Human SirT3 is a
mitochondria protein with its closest homolog being SirT1, with
its N-terminal 25 amino acid residues partially responsible for its
mitochondrial localization [12,13]. Synthesized as an enzymati-
cally inactive protein, human SirT3 is activated by a mitochon-
drial matrix-processing peptidase[12]. Compared with human
SirT3, however, murine SirT3 lacks the N-terminal 142 amino
Figure 3. The NAD+ -dependent Sir2 -like mitochondria protein deacetylase, SirT3, rescues EJ-p53 from p53 –inducible growth
arrest. The human SirT3 2.9 kb cDNA identified in the retroviral screen (Fig. 2) was placed in the MSCV retroviral plasmid using a bicistronic cassette
with GFP (Green fluorescent protein). EJ-p53 cells were transduced with MSCV particles containing only GFP, mouse c-myc and human SirT3. Cell
growth kinetics were determined by laser scanning florescence microscopy (A) and by monitoring cell populations (B). (C)[
3H]-thymidine
incorporation studies were assayed after 72 hours in EJ-p53 cells following transduction with indicated retroviruses followed by induction of p53
expression by tetracycline withdrawal for 72 hours. (D) SA-b galactosidase activity were determined in retroviral transduced EJ-p53 with MSCV-GFP/
Sirt3 transduced into EJ-p53 cells prior and following induction of p53 by tetracycline withdrawal.
doi:10.1371/journal.pone.0010486.g003
Regulation of p53 by Sirt3
PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10486acid residues necessary for the mitochondria localization for the
human version. Nevertheless, the murine SirT3 was shown to
maintain a paranuclear localization, consistent with a mitochon-
drial distribution pattern [12].
To determine further whether SirT3 has the capacity to avert
growth arrest and to extend cell longevity we evaluated the role of
SirT3 to increase the replicative potential of EJ-p53 cells. Shown
in Fig. 3 we infected EJ-p53 cells (5610
5 cells per 30 mm well/
MOI 50 particles per cells) 24 hours prior to tetracycline
withdrawal with three separate retroviruses shown carrying the
bicistronic EGFP cassette lacking an insert (MSCV-GFP) and
carrying either the full length human SirT3 (MSCV-GFP/hSirT3)
or c-myc (MSCV-GFP/c-myc) cDNAs. After 24 hours of infection
tetracycline was withdrawn from the medium for the induction of
p53 and cell numbers were measured by fluorescence microscopy
(Figs. 3A and 3B). After 72 hours, cell populations were
monitored by fluorescence microscopy and indicate the capacity
of both SirT3 and c-myc to avert the p53 –induced cell growth
arrest in the EJ-p53 cells, whereas, the control virus containing the
GFP cassette alone failed to engage cell proliferation. To
accurately monitor the the EJ-p53 cell population following
transduction by MSCV-GFP, MSCV-GFP/SirT3, and MSCV-
GFP/c-myc and after 24 hours of induced p53 expression the EJ-
p53 cell population was counted to determine the cell doublings.
Results show that MSCV-GFP/c-myc can immortalize the EJ-p53
cell line after p53 induction, whereas, MSCV-GFP/SirT3
extended the doubling potential of the EJ-p53 cells for 10 days
before succumbing to growth arrest (Fig. 3B). However, the
MSCV-GFP control shows that cell doublings continue only over
a short period of two days after induction of p53 expression. These
data are consistent with the microscopy results (Fig. 3A)
suggesting that SirT3 can avert p53 –induced growth arrest to
extend the proliferative potential of the EJ-p53 cells. To
demonstrate whether cell doublings are consistent with the DNA
replicative potential of cells transduced with MSCV-GFP, MSCV-
GFP/SirT3 and MSCV-GFP/c-myc,[
3H]-thymidine incorpora-
tion studies were conducted. Results here indicate that [
3H]
thymidine incorporation is greatest with those cells transduced
with GFP/c-myc after 24 hours of the induction of p53 expression
(Fig. 3C). However, transduction of EJ-p53 with MSCV-GFP/
Sirt3 was comparatively less than with GFP/c-myc but substantially
greater than the control MSCV-GFP vector. Therefore, our
results suggest that SirT3 expression can avert growth arrest by
p53, however, the extension in cellular lifespan is temporary and
can not immortalize the cells like MSCV-GFP/c-myc (Fig. 3B).
Explanation of this may be due to the fact that upon p53
expression the temporary rescue from p53 growth arrest maybe
confined to the mitochrondria localization. The nuclear localiza-
tion of p53 may overcome the initial subcellular fraction of p53 in
the mitochrondria to direct p53 senescence programs in the
nucleus. SirT3 expression prior to p53 induction was required to
completely avert growth arrest in the EJ-p53 cells (Fig. 3D).
Therefore, the results indicate that commitment of cell fate is
determined upon initial expression of p53 or SirT3. Hence, the
expression of SirT3 is required prior to induction of p53 to avert
the p53-mediated growth arrest phenotype (Fig. 3D).
SirT3 associates with Bcl2 and p53 in vivo
Identification of the retroviral clone A478-34 as the SirT3
cDNA reveals that mammalian SirT3 may have a direct role in
regulating p53 –induced cell growth arrest in the EJ-p53 cell line.
Furthermore our studies indicate that SirT3 can direct cell fate
prior to the inducible cell growth arrest by p53, as shown (Fig. 3).
New evidence reveals that p53 may be acetylated at the post-
translational level prior to entering the nucleus. This finding has
important implications for p53 –mediated senescence since
acetylation of p53 at the intracellular level plays a critical role in
navigating senescence by p53. As a result a large amount of effort
was needed to create the necessary reagents to appropriately
investigate this new area of p53 function. Specifically, it was
necessary to produce new antisera for the post-translational
modifications of p53 not commercially available. This includes
antisera for the acetylated form of p53 unique to the mitochondrial
form of p53 in the cell model used. Our study indicates that p53 is
a unique target for the anti-senescence protein deacetylase called
SirT3 (Fig. 4). SirT3, like the Sirt1 protein (previously known to
deacetylate p53 in nucleus) can also deacetylate a synthetic peptide
corresponding to p53 (Fig. 4A). However, this deacetylation by
SirT3 seems to occur in the mitochrondria (Fig. 4C). New
reagents for these novel investigations now require the generation
of new expression vectors for both SirT3 and p53 as well as other
targets for p53 function in the mitochrondria. These results
indicate post-translational acetylation of p53 is significant for
understanding the role of p53 in mitochrondria in promoting
growth arrest.
Our results show the localization of p53 with the mitochondrial
sirtuin protein, SirT3, is directly coupled to deacetylation of p53 in
the mitochondrial compartment within the EJ-p53 cell line
(Fig. 4A–D). Furthermore, we detect direct interactions between
SirT3 and p53 through the MASD region of p53. (Fig. 2D). The
lack of evidence from previous studies to support this claim [31]
may have been due to the lack of high-quality antibody reagents to
detect specific modifications of p53, which became available only
after the previous studies. Although It is still unclear why
antibodies directed at acetylated p53 failed to detect the acetylated
species in the earlier report [31], one explanation may be
conformational differences between nuclear and mitochondrial
species of p53. However, recent evidence points to a role for the
monoubiquitylation of p53 for trafficking to mitochrondria
followed by deubiquitylation and stabilization of p53 with HAUSP
[43] and may, therefore, indicate a transition to a monoubiqui-
tated p53. This is an important finding given how little is known
regarding p53 function in the mitochrondria even with important
recent advances [43,44]. There is even less known regarding the
state of p53 acetylation in mitochrondria and the potential for
signaling between modified species of p53. Previous studies have
documented the interactions and deacetylation of p53 by Sirt1
[45,46]. However, the biological implication of this are being
challenged and suggest a more complicated mechanism for sirtuin
protein regulation of p53 in vivo [5]. Our result now shows that p53
co-localizes with the protein deacetylase SirT3 in the mitochron-
dria prior to enacting irreversible growth arrest (Fig. 4D). Affinity
purification and co-immunpreciptation studies of p53 and SirT3
illustrate the interactions between SirT3 and p53 in mitochondrial
fractions (Fig. 4A). For confirmation of mitochondrial p53
interaction with mtHSP70 we show that the interaction between
mtHSP70 and p53 is detectable (Fig. 4A). Comparatively, the
relative absence of SirT3 in the nucleus indicates that this
interaction may only take place in mitochrondria upon cellular
stress [16], which is likely a consequence of elevated p53
expression in the EJ cells; whereas, Sirt1 co-fractionates with
p53 in the nucleus (Fig. 4B). These results also confirm that the
deacetylase activity expressed by SirT3 can deacetylate a specific
p53 peptide sequences previously acetylated by histone acetyl-
transferases CBP and PCAF (Fig. 4C). Recent studies now
indicate the functional capacity of cytosolic CBP/p300 to acetylate
the type I interferon receptor to enforce signaling through the IFN
enhancesome [47]. However, attempts to identify and define
Regulation of p53 by Sirt3
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(A). Total cell lysate from (+)tet, (-)tet 6 h and 24 h EJ-p53 cells were collected and solubilized in lysis buffer containing complete proteolysis inhibitor.
Monoclonal antibody against human p53 (DO1) and then protein G-agarose beads were added to the sample. The immunoprecipitated proteins from
the washed beads were separated on a 10% gel, then transfer to filters for immunoblotting. Blots were blocked and probed with anti-p53 (mouse
monoclonal DO-1), polyclonal rabbit anti-mthsp 70 (HSPA9) and mouse monoclonal anti-Bcl 2 (clone 124, Dako USA) and anti- SirT3 followed by HRP-
conjugated anti-goat, HRP-conjugated anti-mouse and HRP-conjugated anti-rabbit, and then developed using ECL. (B). Total cell, nuclear, and
mitochondrial fractions were obtained from EJ-p53 cells after 12 hours of tetracycline withdrawal and p53 expression. Each fractionated lysate was
analyzed by SDS-PAGE and immunoblotted with antibodies against p53, SirT1 and SirT3. (C) Protein deacetylase activity was measured against a
synthetic peptide corresponding to the human p53 protein sequence (HLKSKKGQSTSRHKKLMFK-C*) radiolabeled with [
14C]-acetylCoA (GE
Healthcare) and purified acetyltransferases CBP and PCAF in vitro. Deacetylase activity was determined from mitochondrial and nuclear fractions
taken from EJ-p53 cells following 12 hours after induction of p53 expression by tetracycline withdrawal. Deacetylase activity was determined from
Regulation of p53 by Sirt3
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acetylated species of p53 using combinations of polyclonal
antibodies recognizing acetylated p53 for SirT3 -mediated
deaceylation, yet SirT3 can deacetylate p53 in vitro. Recently, it
has been suggested that SirT3 may distinguish between basal versus
stress –induced apoptotic pathways evaluated in different cancer
and epithelial cell lines and may be the result of maintaining
control of the apoptotic pathway induced through the absence of
Bcl2 [48]. However, the salvage of NAD+ levels in mitochrondria
through the NAM phosphosribosyltransferase gene product
(Nampt) requires intact SirT3 for maintaining an anti-apoptotic
response to increase cellular survival [49]. In light of these
discrepancies in the outcome of cellular survival from these studies
further global proteomic analyses hope to distinguish pathways
and proteins essential for mediating cell survival by SirT3.
Interaction of p53 with BCL2 -associated athanogene
(BAG-2) is mediated through the MASD of p53 to
abrogate deacetylation of p53 by SirT3
As a result of our studies to identify domains necessary for p53
to execute cell growth arrest in the EJ-p53 cell line (Fig. 5), we
wanted to identify potential interacting partners for p53 through
the mitchrondrial –associated senescence domain (MASD) of p53.
Using a yeast two -hybrid interaction assay, we utilized the
fragment of p53 between amino acids 64–209 as the bait for
determining protein interactions. Our hypothesis is that protein
interactions mediated through this region of p53 may influence
p53’s ability to direct mitochondrial –associated senescence
(MAS). After screening with the yeast two-hybrid interaction
assay, we had identified 14 candidates. Since our initial
expectation was the possibility of re-identifying SirT3 as a
candidate among those isolated clones, sequence analysis of
several positive interactions resulted in the identification of one
candidate protein called BCL2-associated athanogene 2 (BAG-2).
Although, BAG-2 has never been shown to be associated with p53,
recent studies show that BAG -related proteins compete with Hip
for binding to the Hsc70/Hsp70 ATPase domain and promote
protein substrate release involving both the chaperoning, folding,
and degradation of wild type and mutant p53 [24,25]. BAG-2,
which is an auxiliary subunit of the carboxyl terminus of Hsp70-
interacting protein complex (CHIP), functions as a co-chaperone
for specific protein substrates to provide a means of interfering
with proteosomal degradation [26]. In our study we identify BAG-
2 as interacting with p53 in the EJ-p53 cells following induction of
p53 (Fig. 5A). This activity seems coupled to the stability of p53 as
shown (Fig. 5B). We show that BAG-2 influences the stability of
p53 after 24 hours following tet withdrawal whereas p53 mRNA
remains unaffected (Fig. 5B). To see if there is any abrogation of
p53 function to induce growth arrest in the EJ-53 cells, thymidine
incorporation analysis indicates that inhibition of BAG-2 by RNA
interference (RNAi) increases thymidine incorporation as an index
of cell proliferation (Fig. 5C). Furthermore, using an earlier time
point of 18 hours following tet withdrawal we see a direct
correlation between BAG-2 inhibition and the reduction in
acetylated p53 species (Fig. 5D). This activity was further
augmented by the infection with MSCV-hSirT3 retrovirus
(Fig. 5D). Indicating that BAG-2 increases intracellular levels of
acetylated p53 in direct contrast to the decrease seen following
infection with SirT3 retrovirus (Fig. 5D). In accordance with
evidence shown (Fig. 5D) for specific p53 deacetylation, we tested
whether the SirT3 lysine deacetylase activity from human
embryonic lung fibroblasts IMR-90 transduced with the MSCV-
SirT3 retrovirus is specific for mitochondrial p53. Shown are the
sub-cellular mitochondrial and nuclear fractions taken from cells
infected MSCV-SirT3 and MSCV and assayed for pan –
acetylated p53, along with protein landmarks corresponding to
the nucleus and mitochondria purity. Our results demonstrate that
p53 deacetylation by SirT3 is restricted to mitochondria and not
the nucleus of EJ-p53 cells induced for p53 expressionafter
24 hours (Fig. 5E). The contribution of BAG-2 in directing some
p53 activity suggest a role for BAG-2 and CHIP in maintaining
native conformation possibly to stabilize p53 into a folded native
condition associated with cellular stress. Despite the central role of
Mdm2 in proteasomal targeting of p53, additional ubiquitin ligases
were recently shown to participate in the degradation of the tumor
suppressor in normal cells, including p300, Pirh2, and COP1 [24].
Although p300 seems to cooperate with Mdm2 during ubiquityla-
tion, Pirh2 and COP1 trigger the destruction of p53 independent
of Mdm2. Multiple degradation pathways apparently exist to
maintain low levels of p53 in normal cells. It is unclear whether
these degradation pathways are truly redundant or whether they
are selectively engaged in p53 destruction dependent on cell
lineage, developmental stage, or physiological situation. The
complexity of p53 degradation may reflect the regulation and
integration of diverse p53-mediated signaling pathways. Interest-
ingly, we had identified mtHsp40 (Tid1), as this manuscript was
being prepared, as an interacting protein with p53 (not shown) now
confirmed to interact with cytosolic p53 under hypoxic conditions
[27]. Future experiments will now take into consideration the
network of different chaperones for p53 as a client protein that
may monitor the quality control and salvage of p53 to enforce the
activities for p53 in mitochondria.
Protein degradation in the mammalian cytoplasm and nucleus
involves cooperation of the molecular chaperones Hsc70 and
Hsp90 with the ubiquitin-proteasome system [50]. Of central
importance to this degradation pathway is the chaperone-
associated ubiquitin ligase CHIP [51]. Through binding to the
carboxyl termini of Hsc70 and Hsp90, CHIP mediates the
ubiquitylation of chaperone-bound client proteins in conjunction
with E2 enzymes of the Ubc4/5 family and induces client
degradation by the 26 S proteasome [51]. Affected chaperone
clients can be broadly divided into two subclasses: (i) Hsc70- and
Hsp90-associated signaling proteins, for example the glucocorti-
coid hormone receptor and the oncogenic receptor tyrosine kinase
ErbB2 and (ii) aggregation-prone proteins that are subjected to
chaperone-assisted quality control, such as misfolded cystic fibrosis
transmembrane conductance regulator (CFTR) and hyperpho-
sphorylated tau. However, the full range of cellular substrates of
CHIP remains to be explored. Remarkably, mice that lack CHIP
develop apoptosis in multiple organs after environmental chal-
lenge [52]. This seems to reflect the role of CHIP in the
conformational regulation of the heat shock transcription factor
but may also mirror altered associations between the chaperone
machinery and diverse apoptosis regulators in the absence of
CHIP [53]. As an intrinsic mediator of CHIP activity BAG-2 plays
a role in regulating access of CHIP to client proteins [26]. All the
p53, Sirt1, and Sirt3 immunopreciptates taken from nuclear and mitochondrial fractions. (D) Co-localization of p53 and SirT3 was performed by
transient expression of human Sirt3 tagged with the Green Fluorescent Protein (GFP) and visualized by laser confocal microscopy. Inducible
expression of p53 was monitored after 6 and 24 hours post-induction through the withdrawal of tetracycline (Tet) from growth medium. Separate
images at each wavelength were merged to determine the signal overlay.
doi:10.1371/journal.pone.0010486.g004
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10486Figure 5. Human BAG-2 associates with p53 and stabilizes the level of p53 in vivo. (A) EJ-p53 cells were cultured to induce p53 expression
upon withdrawal of tetracycline after 24 hours. As shown, input level of p53 and human BAG-2 are shown from total cell lysates obtained from the EJ-
p53 cells in the presence (+tet) or withdrawal of tetracycline (-tet) from culture medium for EJ-p53 cells. Immunoblots were conducted with antisera
against p53 and BAG-2 from 50 mg of total cell lysate. Bottom, shown is an immunoprecipitation conducted with anti -p53 followed by
immunoblotting with anti –BAG-2 antibodies. (B) RNA interference (RNAi) of human BAG-2 was conducted with siRNAs (Ambion, sequence ID#137542)
directed at endogenous human BAG-2 mRNA in the presence of p53 expression within EJ-p53 cells. Cells were maintained at 40% confluent growth in
5% CO2 and transfected with 7 mg of the 21nt siRNA in 30 mm Petri dishes. The control sample is representative of a transfection using scrambled 21nt
RNA mixture provided by the manufacturer. In parallel cultures, both total cell RNA and protein was recovered and used to measure mRNA and protein
levels by northern hybridization using cDNA probes for human BAG-2, HPRT, and p53 and immunoblotted with the antibodies corresponding to BAG-2,
HPRT, and p53, respectively. (C) Thymidine incorporation into nascent genomic DNA was measured upon introduction of siRNA targeted against BAG-2
and scrambled RNAs in EJ-p53 cells induced for the expression of p53 after 24 hours. Values reflect the relative incorporation of [
3H] thymidine versus
DNA content. (D) Total cellular content of acetylated and total following induction of p53 in EJ-p53 cells and infection with the MSCV –hSirt3 retrovirus
or transfection with small interfering RNAs (siRNA) against human BAG2 (BAG2 RNAi). Antibody against acetylated p53 as described was used to detect
acetylated species of p53. (E) As shown in panel D, Human embryonic lung fibroblasts IMR-90 cells were infected with MSCV-SirT3 and the MSCV
control vector. Sub-cellular mitochondria and nuclear fractions were isolated and collected. Immunoblots confirming the presence of pan-acetylated
p53, Lamin B1 and adenine nucleotide translocase (ANT) are shown from each sub-cellular fraction.
doi:10.1371/journal.pone.0010486.g005
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near the C terminus but differ markedly in their N-terminal
regions. The predicted BAG-2 protein contains 211 amino acids
[26]. The BAG domains of BAG-1, BAG-2, and BAG-3 interact
specifically with the Hsc70 ATPase domain in vitro and in
mammalian cells. All 3 proteins bind with high affinity to the
ATPase domain of Hsc70 and inhibit its chaperone activity in a
Hip-repressible manner, thereby providing a plausible mechanism
for restricting p53 degradation. [24].
Methods
Cell culture
Use of the human bladder tumor-derived EJ-p53 cells,
previously described elsewhere [2,33], were derived from the
human EJ bladder carcinoma cells, from that express a
tetracycline (tet)-regulated wild-type p53 were generously provided
by Dr. Stuart Aaronson (Mount Sinai School of Medicine). All cell
cultures were maintained in DMEM containing 10% FBS and
tetracycline or doxycycline (Sigma-Aldrich) (1 mg/ml). EJ-p53 cells
were induced to express p53 by rinsing three times with PBS
(without calcium and magnesium) and then replacing with
tetracycline/doxycycline -depleted medium. EJ-p53 cells became
senescent within 3–4 days of sustained p53 expression [2,33]. The
human IMR-90 cell line was purchased through American Type
Culture Collection (ATCC) and cultured by standard cultivating
techniques using media reagents and instructions provided by the
supplier. Introduction of various p53 deletions by transient
transfection as described previously were used to monitor p53
function [54]. An additional deletion was created to remove amino
acids 64 through 209 by using PCR deletion strategy and the
Quickchange mutagenesis kit (Stratagene).
Subcellular and biochemical fractionation
Mitochondrial fractionation was achieved using the proce-
dures essentially as described with the modifications described
here [29,55]. Sucrose step gradient was performed on EJ-p53
cells at different time points after induction of p53 by removal of
tetracycline from the culture media (referred to as –tet),
including 0 h (, +tet, control), -tet 2 h, 4 h, 6 h, 1 d, 2 d, 3 d,
4 d. The 1 ml pellet of cells was washed in 10 to 20 ml of TD
b u f f e r( 1 3 4m MN a C l ,5m MK C l ,0 . 7m MN a 2HPO4,2 . 5m M
Tris-HCl, pH 7.5) and centrifuged for 5 min at 2.5 krpm in a
Sorvall centrifuge. Cells were resuspended in 10–12 ml of MgRS
B u f f e r ( 1 0m M N a C l , 1 . 5m M M g C l 2,1 0 m MT r i s - H C l ,
pH 7.5) and incubated for 10 min. Swollen cells were disrupted
in a glass Dounce homogenizer to yield approximately 95% free
nuclei as judged by phase contrast microscope. 2.56MS buffer
was added to a final concentration of 0.21 M mannitol, 0.07 M
sucrose, 5 mM Tris-HCl,pH 7.5. Nuclei was isolated by two
successive sedimentations of 5 min each at 3,000 rpm and
recovered for further purity using the nuclear extraction kit
(Imgenex) according to manufacturer’s instructions. The super-
natant was then centrifuged at 10,000 rpm for 20 min, and the
pellet was resuspended in 3 ml 16 MS buffer. Loading 3 ml of
1.5 M sucrose solution on the bottom of the tube, the 3 ml of
1 M of sucrose was loaded on the interphase, and the sample was
loaded on the sucrose cushion and centrifuged further at
22,000 rpm (110,0006g) at 4uC for 30 min. Mitochondria
fractions were collected between the 1–1.5 interphase and
sample was washed with 4 volumes of the MS buffer.
Alternatively, mitochondrial fractions were recovered using the
MITOISO1H Mitochondria Isolation Kit (Sigma) according to
the manufacturer’s instructions.
Immunoblot analysis
Mitochondrial and nuclear fractions in addition to total cell
lysate from each of the time points indicated and conditions used
were electrophoresed using SDS-PAGE. Protein quantitation was
performed using the BCA protein assay (Pierce). Between 25 –
50 mg of protein per sample was subjected to 10% SDS-PAGE and
transfer to a polyvinylidene difluoride filter (PVDF) (Millipore).
The filter was blocked in 10% milk/0.1% Tween 20/PBS followed
by incubation with the different primary antibodies as indicated
p53-specific mouse monoclonal DO-1 (Leica Microsystems); pan-
acetylated p53 rabbit polyclonal antisera (lys 320, 373, 382,
mixture of Millipore cat nos. 06-758, 06-915); cyclooxygenase
subunit II (Cox II) (70 kD subunit, mouse monoclonal, clone
AS66, Sigma-Aldrich); mtHsp70 (anti-HSPA9, Sigma-Aldrich);
PCNA (mouse monoclonal, clone PC-10, Cell Signaling); 4) SirT3
(Sirtuin 3, cat no. ab75434, AbCam); Adenine dinucleotide
translocase (mouse monoclonal, clone 5F51BB5AG7, MitoS-
ciences); Lamin B1 (cat no. ab16048, AbCam). After three times
washes, the blot was incubated with HRP-conjugated anti-mouse
for mouse monoclonal antibodies or HRP –conjugated anti-rabbit
for rabbit polyclonal antibodies, respectively (Pierce). Immunode-
tection was performed and then developed using the ECL system
(GE Healthcare).
In Vitro Protein-Protein Binding Assays
The construction of the glutathione S-transferase (GST)-p53
fusion was performed by standard PCR and cloning techniques
constructed by cleavage of the pGEX-6P1 vector and the target
DNA at appropriate restriction sites and ligation using standard
recombinant DNA methodology. The GST fusion proteins were
expressed in Escherichia coli strain BL21, and were purified and
immobilized to glutathione-agarose as described previously.
35S-
Radiolabeled full-length SirT3 was synthesized in vitro by use of a
coupled transcription/translation system (TnT kit, Promega). The
35S-labeled proteins were then incubated with 50 ml of a 50%
slurry of the corresponding immobilized GST fusion protein in
200–300 ml of HEMG binding buffer (40 mM HEPES, pH 7.8,
50 mM KCl, 0.2 mM EDTA, 5 mM MgCl2, 0.1% Triton X-100,
10% glycerol, 1.5 mM dithiothreitol, 16 Complete Protease
Inhibitor (Roche Biochemical), and 0.5 mg/ml bovine serum
albumin) for 1 h at 4uC with gentle rocking. The agarose beads
were then washed four times with 1 ml each of HEMG buffer in
the absence of protease inhibitor and bovine serum albumin.
Bound proteins were eluted in 30 ml of 50 mM Tris-HCl (pH 6.8)
containing 100 mM glutathione, were resolved by SDS-polyacryl-
amide gel electrophoresis, and were visualized and quantified by
PhosphorImager analysis.
Mitochondrial labeling with CMTMR
Chloromethyl- tetramethylrosamine methyl ester (CMTMR) is
a fluorescent potentiometric dye that specifically stains mitochon-
dria in live cells. Procedure was carried as previously described
[28] and according to manufacturer’s instructions (Mitotracker
Orange; Molecular Probes, Invitrogen). Further immunocyto-
chemistry with selected antibodies (as indicated) was performed as
described previously [28] and briefly explained here. Coverslips
containing paraformaldehyde treated cells were blocked with 10%
goat serum at room temperature for 1 hour. Primary antibody
mouse monoclonal anti-p53 antibody, 1801, 1:1000 (Oncogene
Research) was used. The coverslips were then washed 3 times with
1% NP-40 in PBS and incubated with the second antibody Cy5
goat anti-mouse Ig G (Amersham): 1:250 at 37uC in a humidified
chamber for 1 hour. Finally, coverslips were washed with 1% NP
40 in PBS three times. DNA/Nucleus staining was performed with
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to manufacturer’s instructions. The coverslips were placed in 24
well plates, and PBS was removed from each well, ice cold 100%
methanol was then added and immediately removed, then 200 ml
YOYO working solution (1.5 mM) was placed over fixed cell
populations for 30 min at 22 C in a darkroom. The coverslips
were rinsed 3 times with PBS and the coverslips were mounted
onto glass microscope slides using a proper fluorescent mounting
medium.
Laser Scanning Confocal Microscopic Imaging (LSCM)
CMTMR staining, YOYO staining and immunofluroescence
staining were imaged using a LSCM as previously described [28]
All cells were imaged at the same levels of laser intensity, detector
sensitivity, and pinhole size in order to ensure that fluorescence
intensity could be compared among different coverslips. The
images were saved as high resolution TIFF files and then analyzed
using Northern Eclipse software (version 2.1, Empix Imaging, Inc.,
Mississauga, CANADA).
Genetic screening for the rescue of p53 -induced cellular
senescence
10
8 EJ-p53 prior to tetracycline withdrawal were infected with a
MaRX retroviral library (complexity 6610
6) prepared from mouse
embryos [38]. The efficiency of infection was approximately 25%.
At day 3 after infection, plates were split 1:2 and cultured in the
presence of 20 g ml
21 hygromycin B (Sigma, St Louis, MO). Cells
were split every five days until proliferation of control cells
stopped. Proliferating cells from the library-infected plates were
pooled and genomic DNA was purified using the blood and cell
culture DNA mini kit (Qiagen, Valencia, CA). Genomic DNA
(5 mg) was treated with Cre recombinase, phenol extracted,
ethanol precipitated, and used to transform DH10B-lac-trfA.
Proviruses were recovered from zeocin-resistant bacterial colonies.
From all the recovered plasmids, retroviral clone A478-34
(encoding full-length mouse SirT3) was one of three confirmed
positive retroviruses.
Cell culture, retroviral infection, growth curve analysis,
and senescence –associated (SA) b galactosidase staining
The human SirT3 2.9 kb cDNA identified in the retroviral
screen was placed in the MSCV retroviral plasmid using a
bicistronic cassette with GFP (Green fluorescent protein) [56]. EJ-
p53 cells were transduced with MSCV particles containing only
GFP, mouse c-myc and human SirT3. Cumulative population
doublings per passage were calculated as log2 (number of cells at
time of subculture/number of cells plated) and plotted against total
time in culture to assess replicative lifespan. Cell growth kinetics
were determined by laser scanning florescence microscopy for
GFP and by monitoring cell populations. [
3H]-thymidine
incorporation studies were assayed after 72 hours essentially as
described [57] in EJ-p53 cells following transduction with
indicated retroviruses followed by induction of p53 expression by
tetracycline withdrawal for 72 hours. SA-b galactosidase activity
were determined in retroviral transduced EJ-p53 with MSCV-
GFP/SirT3 transduced into EJ-p53 cells prior and following
induction of p53 by tetracycline withdrawal using the senescence –
associated b-galactosidase Staining Kit (Cell Signaling Technolo-
gy) according to manufacturer’s instructions.
Protein deacetylase assays of p53
Protein deacetylation reactions were performed essentially as
previously described [58,59]. Protein deacetylase activity was
measured against a synthetic peptide corresponding to the human
p53 protein sequence (HLKSKKGQSTSRHKKLMFK-C) was
synthesized and purified by HPLC (Pepitogenic, Inc.). Purified
synthetic peptide was radiolabeled with [
14C] -acetylCoA (GE
Healthcare) and subjected to enzymatic reactions with purified
acetyltransferases CBP and PCAF in vitro using procedures
previously described [60]. Deacetylase activity was determined
from mitochondrial and nuclear fractions taken from EJ-p53 cells
following 12 hours after induction of p53 expression by tetracy-
cline withdrawal. Deacetylase activity was determined from p53,
Sirt1, and Sirt3 immunopreciptates taken from nuclear and
mitochondrial fractions.
Acknowledgments
We gratefully acknowledge Eric Verdin (UCSF, San Francisco, CA) and
Jesus Gil (Clinical Sciences Centre, MRC, London, UK) for generously
providing reagents. We especially thank Ms. Yang Wang and Dr. Yubin
Guo for technical assistance and with some experimental designs.
Author Contributions
Conceived and designed the experiments: SL MMS MJW. Performed the
experiments: SL SM MMS MJW. Analyzed the data: SL MB SM MMZ
MMS MJW. Contributed reagents/materials/analysis tools: SL MB SM
MMZ MMS MJW. Wrote the paper: SL MMS MJW.
References
1. Talos F, Petrenko O, Mena P, Moll UM (2005) Mitochondrially targeted p53
has tumor suppressor activities in vivo. Cancer Res 65: 9971–9981.
2. Sugrue MM, Shin DY, Lee SW, Aaronson SA (1997) Wild-type p53 triggers a
rapid senescence program in human tumor cells lacking functional p53. Proc
Natl Acad Sci U S A 94: 9648–9653.
3. Moll UM, Wolff S, Speidel D, Deppert W (2005) Transcription-independent
pro-apoptotic functions of p53. Curr Opin Cell Biol 17: 631–636.
4. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, et al. (2002) Human
SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.
Embo J 21: 2383–2396.
5. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, et al. (2006)
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter
cell survival following DNA damage. Mol Cell Biol 26: 28–38.
6. Buck SW, Gallo CM, Smith JS (2004) Diversity in the Sir2 family of protein
deacetylases. J Leukoc Biol 75: 939–950.
7. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA (2003)
Nicotinamide and PNC1 govern lifespan extension by calorie restriction in
Saccharomyces cerevisiae. Nature 423: 181–185.
8. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005)
Evolutionarily conserved and nonconserved cellular localizations and functions
of human SIRT proteins. Mol Biol Cell 16: 4623–4635.
9. Moazed D (2001) Enzymatic activities of Sir2 and chromatin silencing. Curr
Opin Cell Biol 13: 232–238.
10. Shore D (2001) Telomeric chromatin: replicating and wrapping up chromosome
ends. Curr Opin Genet Dev 11: 189–198.
11. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, et al. (2003)
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-
deficient mice. Proc Natl Acad Sci U S A 100: 10794–10799.
12. Schwer B, North BJ, Frye RA, Ott M, Verdin E (2002) The human silent
information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide
adenine dinucleotide-dependent deacetylase. J Cell Biol 158: 647–657.
13. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP (2002) SIRT3, a
human SIR2 homologue, is an NAD-dependent deacetylase localized to
mitochondria. Proc Natl Acad Sci U S A 99: 13653–13658.
14. Shi T, Wang F, Stieren E, Tong Q (2005) SIRT3, a mitochondrial sirtuin
deacetylase, regulates mitochondrial function and thermogenesis in brown
adipocytes. J Biol Chem 280: 13560–13567.
15. Vaquero A, Sternglanz R, Reinberg D (2007) NAD+-dependent deacetylation of
H4 lysine 16 by class III HDACs. Oncogene 26: 5505–5520.
16. Scher MB, Vaquero A, Reinberg D (2007) SirT3 is a nuclear NAD+-dependent
histone deacetylase that translocates to the mitochondria upon cellular stress.
Genes Dev 21: 920–928.
Regulation of p53 by Sirt3
PLoS ONE | www.plosone.org 11 May 2010 | Volume 5 | Issue 5 | e1048617. Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP (2008)
SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells
from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol 28:
6384–6401.
18. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, et al. (2009) Sirt3
blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent
antioxidant defense mechanisms in mice. J Clin Invest 119: 2758–2771.
19. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, et al. (2007)
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine
acetylation. Mol Cell Biol 27: 8807–8814.
20. Hallows WC, Lee S, Denu JM (2006) Sirtuins deacetylate and activate
mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A 103:
10230–10235.
21. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E (2006) Reversible
lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA
synthetase 2. Proc Natl Acad Sci U S A 103: 10224–10229.
22. Lavin MF, Gueven N (2006) The complexity of p53 stabilization and activation.
Cell Death Differ 13: 941–950.
23. Walerych D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, et al. (2004)
Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 279:
48836–48845.
24. Esser C, Scheffner M, Hohfeld J (2005) The chaperone-associated ubiquitin
ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 280:
27443–27448.
25. Tripathi V, Ali A, Bhat R, Pati U (2007) CHIP Chaperones Wild Type p53
Tumor Suppressor Protein. J Biol Chem 282: 28441–28454.
26. Arndt V, Daniel C, Nastainczyk W, Alberti S, Hohfeld J (2005) BAG-2 acts as an
inhibitor of the chaperone-associated ubiquitin ligase CHIP. Mol Biol Cell 16:
5891–5900.
27. Ahn BY, Trinh DL, Zajchowski LD, Lee B, Elwi AN, et al. (2009) Tid1 is a new
regulator of p53 mitochondrial translocation and apoptosis in cancer. Oncogene.
28. Sugrue MM, Wang Y, Rideout HJ, Chalmers-Redman RM, Tatton WG (1999)
Reduced mitochondrial membrane potential and altered responsiveness of a
mitochondrial membrane megachannel in p53-induced senescence. Biochem
Biophys Res Commun 261: 123–130.
29. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, et al. (2003) p53 has a
direct apoptogenic role at the mitochondria. Mol Cell 11: 577–590.
30. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, et al. (2006) WT
p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain
and induce mitochondrial permeabilization. J Biol Chem 281: 8600–8606.
31. Nemajerova A, Erster S, Moll UM (2005) The post-translational phosphoryla-
tion and acetylation modification profile is not the determining factor in
targeting endogenous stress-induced p53 to mitochondria. Cell Death Differ 12:
197–200.
32. Bargonetti J, Manfredi JJ (2002) Multiple roles of the tumor suppressor p53.
Curr Opin Oncol 14: 86–91.
33. Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW, et al. (1999) p21Waf1/
Cip1/Sdi1 induces permanent growth arrest with markers of replicative
senescence in human tumor cells lacking functional p53. Oncogene 18:
2789–2797.
34. Jardine LJ (2004) Identification of senescence in cancer cells. Methods Mol Med
88: 231–238.
35. Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch DH, et al. (2001)
Mammalian prohibitin proteins respond to mitochondrial stress and decrease
during cellular senescence. Exp Cell Res 265: 262–273.
36. Zhu J, Jiang J, Zhou W, Zhu K, Chen X (1999) Differential regulation of cellular
target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity.
Oncogene 18: 2149–2155.
37. Ben-Porath I, Weinberg RA (2005) The signals and pathways activating cellular
senescence. Int J Biochem Cell Biol 37: 961–976.
38. Hannon GJ, Sun P, Carnero A, Xie LY, Maestro R, et al. (1999) MaRX: an
approach to genetics in mammalian cells. Science 283: 1129–1130.
39. Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu
Rev Biochem 73: 417–435.
40. Andersen CL, Hostetter G, Grigoryan A, Sauter G, Kallioniemi A (2001)
Improved procedure for fluorescence in situ hybridization on tissue microarrays.
Cytometry 45: 83–86.
41. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. (2004)
Modulation of NF-kappaB-dependent transcription and cell survival by the
SIRT1 deacetylase. Embo J 23: 2369–2380.
42. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, et al. (2004)
Human SirT1 interacts with histone H1 and promotes formation of facultative
heterochromatin. Mol Cell 16: 93–105.
43. Marchenko ND, Wolff S, Erster S, Becker K, Moll UM (2007) Monoubiquityla-
tion promotes mitochondrial p53 translocation. Embo J 26: 923–934.
44. Marchenko ND, Moll UM (2007) The role of ubiquitination in the direct
mitochondrial death program of p53. Cell Cycle 6: 1718–1723.
45. Gu W, Luo J, Brooks CL, Nikolaev AY, Li M (2004) Dynamics of the p53
acetylation pathway. Novartis Found Symp 259: 197–205; discussion 205-197,
223-195.
46. Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. (2001) Negative control of p53
by Sir2alpha promotes cell survival under stress. Cell 107: 137–148.
47. Tang X, Gao JS, Guan YJ, McLane KE, Yuan ZL, et al. (2007) Acetylation-
dependent signal transduction for type I interferon receptor. Cell 131: 93–105.
48. Allison SJ, Milner J (2007) SIRT3 is pro-apoptotic and participates in distinct
basal apoptotic pathways. Cell Cycle 6: 2669–2677.
49. Yang H, Yang T, Baur JA, Perez E, Matsui T, et al. (2007) Nutrient-sensitive
mitochondrial NAD+ levels dictate cell survival. Cell 130: 1095–1107.
50. Hohfeld J, Cyr DM, Patterson C (2001) From the cradle to the grave: molecular
chaperones that may choose between folding and degradation. EMBO Rep 2:
885–890.
51. Esser C, Alberti S, Hohfeld J (2004) Cooperation of molecular chaperones with
the ubiquitin/proteasome system. Biochim Biophys Acta 1695: 171–188.
52. Dai Q, Zhang C, Wu Y, McDonough H, Whaley RA, et al. (2003) CHIP
activates HSF1 and confers protection against apoptosis and cellular stress.
Embo J 22: 5446–5458.
53. Mosser DD, Morimoto RI (2004) Molecular chaperones and the stress of
oncogenesis. Oncogene 23: 2907–2918.
54. Zhu J, Gao B, Zhao J, Balmain A (2000) Targeting gene expression to tumor
cells with loss of wild-type p53 function. Cancer Gene Ther 7: 4–12.
55. Marchenko ND, Zaika A, Moll UM (2000) Death signal-induced localization of
p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem
275: 16202–16212.
56. Kume A, Hashiyama M, Suda T, Ozawa K (1999) Green fluorescent protein as
a selectable marker of retrovirally transduced hematopoietic progenitors. Stem
Cells 17: 226–232.
57. Walsh MJ, Shue G, Spidoni K, Kapoor A (1995) E2F-1 and a cyclin-like DNA
repair enzyme, uracil-DNA glycosylase, provide evidence for an autoregulatory
mechanism for transcription. J Biol Chem 270: 5289–5298.
58. Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional
silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase.
Nature 403: 795–800.
59. Li S, Moy L, Pittman N, Shue G, Aufiero B, et al. (1999) Transcriptional
repression of the cystic fibrosis transmembrane conductance regulator gene,
mediated by CCAAT displacement protein/cut homolog, is associated with
histone deacetylation. J Biol Chem 274: 7803–7815.
60. Li S, Aufiero B, Schiltz RL, Walsh MJ (2000) Regulation of the homeodomain
CCAAT displacement/cut protein function by histone acetyltransferases p300/
CREB-binding protein (CBP)-associated factor and CBP. Proc Natl Acad
Sci U S A 97: 7166–7171.
Regulation of p53 by Sirt3
PLoS ONE | www.plosone.org 12 May 2010 | Volume 5 | Issue 5 | e10486